Nasdepi

• Nasdepi is the company's standout product, which is biotech because it is used as a medical device to help relieve patients from going to anaphylactic shock. This product is currently being engineered to be more temperature stable, affordable, compact, and fast-acting than the auto injector. This company is highly research and development focused, with a team composed of lab researchers and engineers.

• Nasdepi addresses the problem of high costs associated with anaphylactic allergy response medication. Additionally, Belhaven's mission includes making the product available to more countries, since current EpiPen spread is limited.

• To my knowledge, Belhaven has a fairly unique product in that it delivers a similar medication in a different form. It's main distinguishing point is that it doesn't require a needle to be administered, and is set to be a lower cost.

• I believe in the product and have invested in it, but would be hesitant to work for a small startup fresh out of my graduate school program because of the risk involved with product launch.

Company Website: https://www.twistbioscience.com/

Size of Company (# of employees): 1,000-1,200 (as of 2024)

Location: HQ in San Franciso, CA & additional facilities in Oregon/Internationally

General Areas of Expertise: Twist Bioscience is known for their work in the areas of synthetic DNA production, high-throughput DNA synthesis, genomic libraries, antibody discovery, and biopharmaceutical tools. Their platform employs the use of the silicon-based DNA synthesis process that enables very high-density and scalable DNA synthesis. They work in collaboration with the drug, agricultural, diagnostic, and therapeutic industries.

Twist particularly stands out for the following reasons: It makes DNA on a silicon chip instead of the usual 96 well plates.

This enables 9,600 sequences per chip, a number that is well beyond what competing systems can.

It provides higher fidelity, lower cost, and rapid generation of large libraries and large DNA constructs.

Biotech Product: Twist Custom DNA Synthesis

Would I Work for This Company? Why or Why Not?

Yes, indeed, Twist Bioscience would be an attractive workplace. Their work is at the very forefront of the biotechnology umbrella, and it is directly involved in areas such as gene therapy, synthetic biology, cancer, and personalized medicine. They are known to be at the forefront of technological advancement, collaboration, and making a difference in the area of the biotechnology industry. They are on the right course when it comes to the future of genomic medicine.

Genetically Modified (GM) Corn Seeds

• Biotech b/c using specific genes from other organisms to improve plant traits like disease resistance, yield, etc.

• Problem: crop loss due to pest like the corn borer or corn earworm which can be devastating to crops.

• Similar Products: most major agriculture companies have GM seeds but specifically companies like Corteva, BASF, etc.

• Bayer's is distinguishable because it uses a specific germplasm that can "stack" particular traits like insect resistance with herbicide resistance.

I would like to work for them because I think the work they are doing with regenerative agriculture and also I really enjoy field work which is a big part of this company.

Company website: https://www.vrtx.com

Size of company (# employees): ~ 6,100 

Location of company: Headquarters in Boston, Massachusetts and London, UK

Describe the company’s general area(s) of expertise: 

Vertex is a biopharmaceutical company focused on discovery, development and commercialization of transformative medicines for serious diseases. It is historically best known for cystic fibrosis drugs and, more recently, for advanced cell and gene based therapies. Their work spans small molecule drugs, biologics, and cell/gene therapies.

Choose ONE biotech product produced by this company: CASGEVY^® (cell-based gene therapy)

What makes this product biotech? 

CASGEVY is considered a biotechnology product because it uses CRISPR/Cas9 gene editing to modify a patient’s own stem cells outside the body. It relies on living cells and molecular biology techniques that are engineered to produce a therapeutic effect. This fits directly within the definition of modern biotechnology, where we use biological systems to create innovative solutions.

What problem does this product address? 

CASGEVY is approved to treat sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs), and it has also been approved for transfusion dependent β-thalassemia (TDT). The therapy aims to reduce or eliminate painful VOCs and the need for chronic transfusions by enabling durable production of functional fetal hemoglobin in red blood cells.

Are there similar products available? What distinguishes this one?

Yes, another recently approved cell-based gene therapy for SCD is LYFGENIA^TM from bluebird bio, which uses a lentiviral vector to add/modify genetic material in a patient’s stem cells. Both are one time, ex-vivo autologous stem-cell therapies approved for people ≥ 12 with severe SCD, but they differ in mechanism:

• CASGEVY uses CRISPR/Cas9 genome editing to reactivate fetal hemoglobin. It is also the first FDA approved therapy that uses CRISPR/Cas9.

• LYFGENIA (bluebird bio) uses a lentiviral vector to introduce a functional globin gene (a different molecular approach).

Would you be interested in working for this company? Why or why not?

Yes, I would be interested in working for Vertex Pharmaceuticals. Vertex focuses on cutting edge cell and gene therapies, including the development of completely new treatments like CASGEVY. I want to work in an environment where I can help discover and develop new therapies using molecular biology, gene editing, and innovative biotechnology. Vertex’s emphasis on innovation, effective therapies, and transformative science aligns strongly with the kind of research and impact I hope to contribute to in my career.

Product: Contract‑Manufactured Biologic

• It is produced using living cells through recombinant DNA and cell culture techniques, rather than chemical synthesis.

• It provides large-scale production of biologic therapies, such as monoclonal antibodies or viral-vector vaccines, for diseases that cannot be effectively treated with small-molecule drugs.

• Other CDMOs make biologics, but Fujifilm Diosynth’s offering is distinguished by its large-scale, end-to-end manufacturing capabilities and advanced GMP compliance.

• I would be interested in working at Fujifilm Diosynth because it offers hands-on experience with large-scale cell culture and biologic manufacturing, aligning perfectly with my biotechnology background and career goals.

• About 12,500 employees

• Located in Johnston, Iowa

• The main area of expertise are Seed Genetics and Breeding

Z-Series Soybeans (Product)

• This product contains genetically engineered traits for herbicide tolerance. This seed is tolerant to 2,4-D choline, glyphosate, glufosinate, and sulfonylurea. The traits are inserted into the genes by transgenesis.

• This product addresses problems such as disease pressure and yield instability. This product is resistant to diseases and issues such as sudden death syndrome, brown stem rot, and cyst nematode. This seed increases the average yield by 2.7 bushels per acre.

• There are tons of similar products available, such as Asgrow soybean, but the main difference is that the Z-series can resist more diseases and averages more bushels per acre. It is the leading soybean seed at the moment.

• I would be interested in working for this company because of its seed genetics and breeding, and because the parent company is Corteva Agriscience, a global biotech company. Only issue would be working in Iowa.
  

Biotech Product: Base Editing Platform / BEAM-101

What makes this product biotech?
BEAM-101 uses CRISPR base editing to make a precise, single-nucleotide change in a patient’s blood stem cells. This allows the cells to produce fetal hemoglobin, which can treat blood disorders. Gene editing, cell modification, and therapeutic development are all core biotech processes.

What problem does this product address?
BEAM-101 is designed to treat sickle cell disease and β-thalassemia, two inherited blood disorders caused by mutations in the hemoglobin gene. These diseases can be debilitating and currently have limited treatment options.

Are there similar products available? What distinguishes this one?
Yes—other companies like CRISPR Therapeutics and Vertex (CASGEVY) also target sickle cell using CRISPR. However, those approaches rely on double-strand DNA breaks, which can create unintended mutations.
Beam’s base editing is different because it:

• Does not cut DNA, reducing the risk of harmful off-target effects

• Is more precise, editing a single base

• Has the potential for fewer complications and cleaner edits

This makes Beam’s approach one of the safest forms of gene editing currently being tested.

Would you be interested in working for this company? Why or why not?
Yes, I would be interested in working at Beam Therapeutics. They are developing next-generation gene editing tools that could reshape how genetic diseases are treated. The combination of innovative science, a fast-moving environment, and the chance to contribute to therapies that directly change patients’ lives is extremely appealing. Beam also has a strong presence in North Carolina’s biotech ecosystem, which makes it a realistic and exciting place to grow professionally.

What problem does this product address?
Their devices are used to treat major health issues like chronic nerve pain, limited mobility from neurological injury, arrhythmias, and blocked blood vessels. These problems can severely impact quality of life or lead to life-threatening conditions, so the technology helps restore function and improve patient health.

Are there similar products available? What distinguishes this one?
Other companies make similar devices, but Boston Scientific stands out because they offer a very broad range of technologies across multiple medical specialties. They focus on minimally invasive, clinically proven solutions and have the large-scale research and manufacturing capabilities needed to get these devices to patients around the world.

Would you be interested in working for this company? Why or why not?
Yes, I would be interested in working for Boston Scientific. Their work connects directly to human movement and physiology, which fits well with my background in biomechanics and health science. I like that their products have a direct impact on improving patient mobility and quality of life, which aligns with my own career goals.

• Name of company: Varian Medical Systems, Inc.

• Company website: varian.com

• # of Employees: ~ 10,000 worldwide (after its acquisition by Siemens Healthineers).

• Location of company (headquarters): Palo Alto, California, USA.

• General area(s) of expertise:

  • Radiation-oncology / cancer-treatment technology (radiotherapy, radiosurgery, proton therapy, brachytherapy).

  • Medical imaging components and software (X-ray tubes, digital detectors, image processing) for diagnostics, security/inspection, and medical uses.

  • Oncology software systems and treatment-planning tools (software to plan, verify, deliver radiation therapy) and informatics to manage cancer clinics.

  • Integration of advanced methods (ex. intensity-modulated radiotherapy, image-guided radiotherapy, stereotactic radiosurgery, proton therapy) to deliver precise cancer treatments.

Because of this mixture of medical devices, imaging, software, and radiation-based therapies, Varian occupies a key role in the biotech / med-tech / life-sciences space (especially cancer therapy), even though they are not a biotech based drug company.

What makes this product “biotech / med-tech”?

• TrueBeam is a medical radiation therapy system: it uses high-energy X-rays (or other radiation) to target tumors for cancer treatment. This is a healthcare technology grounded in biomedical physics and engineering. The system integrates hardware (linear accelerator, beam shaping), software (image-guided radiotherapy, treatment planning), and clinical data to precisely deliver radiation bridging biology (tumor biology), medicine (oncology), and advanced technology.

What problem does this product address? It treats cancer by delivering targeted radiotherapy. Many cancers require radiation to kill or shrink tumors while minimizing damage to surrounding healthy tissue. TrueBeam allows clinicians to deliver effective therapy in a controlled, precise way. By enabling advanced techniques (e.g. intensity-modulated radiotherapy, image-guided radiotherapy, stereotactic radiosurgery), it helps improve outcomes (better tumor control) and reduces side-effects (less damage to healthy tissue).

Are there similar products available? What distinguishes this one? Yes, there are other radiotherapy systems and cancer-treatment devices, but Varian’s TrueBeam stands out due to: Integration of hardware + software: TrueBeam isn’t just a radiation machine, it combines beam generation, imaging, motion management, treatment planning, and delivery in a comprehensive platform. Advanced radiotherapy techniques: Varian has pioneered techniques like intensity-modulated radiation therapy (IMRT), image-guided radiotherapy (IGRT), stereotactic radiosurgery (SRS), and volumetric arc therapy (RapidArc) that can deliver highly conformal treatments, critical for complex or sensitive tumors. Global deployment & reliability: Varian has many thousands of linear accelerators in use globally; it’s one of the largest suppliers worldwide.

• Comprehensive oncology ecosystem: Because Varian also offers clinic-management software, planning systems, imaging components, and more, they support not just radiation delivery but the entire workflow of cancer care. That integration can improve efficiency, safety, and quality of care.

Yes, I would consider working for Varian. Their mission, using advanced technology to fight cancer, is deeply meaningful and high-impact. Being part of that means contributing to solutions that could save or extend lives, which is motivating. The company operates at the intersection of engineering, medicine, software, and clinical care. For someone interested in med-tech, biomedical engineering, or health-data/software, that’s a dynamic, multidisciplinary environment. Additionally, there are likely diverse career paths such as, hardware engineering, software, clinical applications, research & development, operations, global support, etc.

Their headquarters is located at Minato-ku, Tokyo. And the factory is in Kyushu Kumamoto Prefecture.

As of March 2025, the company employs about 400 people.

One of their flagship products is a health supplement tablet called ユーグレナのちから("Power of Euglena"), which condenses 59 nutrients in a daily dose and is sold as a functional food!!!

I am interested in working at Euglena Co because it matches my career goals to make an impact in sustainabe environment, using my reaserch background.

It covers areas such as crop protection (including pesticides, herbicides, fungicides, and insecticides), seeds & plant biotechnology, and in many places, also non-agricultural pest control (for horticulture, gardens, and pests, etc.), which extends beyond purely farm agriculture.

Size of the company: 94000+ (Globally)

Major locations for R and D: Germany, California (USA), Belgium, the Netherlands and Research Triangle Park, North Carolina (USA).

Product I want to work on: Genetically enhanced seeds

What makes this product biotech?

Genetic Engineering and Gene editing technologies are involved in the development of these seeds.

What problem does this product address?

Modern seed-breeding and genetically enhanced seed capabilities can thrive in changing environmental conditions and help enhance food production to meet the growing population.

Are there any similar products available? What distinguishes this one?

Yes, companies like Syngenta, Corteva Science work on similar areas. Bayer is working to develop the next generation of crop seeds using a mix of advanced genetics, data science, and AI. Their goal is to create high-yield, climate-resilient plants that can grow well in many different environments and to do it faster than ever before. By combining modern breeding tools with huge amounts of field data, they aim to deliver better, more adaptable seeds to farmers around the world.

Would you be interested in working in this company?

Yes, I would like to work in this company and contribute to developing new modern seeds using CRISPR gene editing technology, which I am currently learning and working on.

:Cell therapy automates pioneers with FDA recognition!

Website: https://oribiotech.com

Location:

1. CIC Philadelphia
   3675 Market St, Suite 200
   Philadelphia, PA 19104

2. MAYDE
   5-10 Brandon Road
   London
   N7 9AA

Size: no data in website but ~50 - < 100 employees

I know this company after joining the online conference and quite impressed in their innovation which is very answer the problem of nowadays challenging in manufacturing field of cell therapy. Here below are what they have got!

1.    Company Focus

Ori Biotech is a biotechnology company dedicated to revolutionizing the manufacturing of cell and gene therapies (CGTs). Their mission is to enable widespread patient access to advanced, life-saving therapies by overcoming the traditional manufacturing bottlenecks inherent in CGT production.

2.    Core Technology / Product: IRO® Platform

• The company’s key innovation is the IRO® platform, a proprietary, fully-automated, closed-system platform designed to standardize and streamline CGT manufacturing.

• IRO automates critical, labor-intensive steps such as cell activation, transduction, expansion, and harvest which enabling a seamless transition from research & development (R&D) scale to Good Manufacturing Practice (GMP) production.

• The platform provides scalability and consistency, combining hardware, consumables, software, and analytics, thus facilitating reproducible production suitable for clinical or commercial use.

3.    Problems Addressed & Therapeutic Impact

• Traditional CGT manufacturing is often limited by high cost, low throughput, and variability, resulting in restricted patient access.

• IRO’s automation and standardization significantly reduce labor requirements (up to 70%), lower cost of goods (up to ~50%), shorten processing time (up to ~25%), and accelerate technology transfer time from months to weeks.

• By alleviating these manufacturing barriers, Ori Biotech helps make cell and gene therapies more scalable, reliable, and accessible — increasing the likelihood that advanced therapies can reach broader patient populations.

4.    Distinguishing Features & Industry Recognition

• In 2025, Ori Biotech’s IRO® platform received the prestigious Advanced Manufacturing Technology (AMT) designation from the U.S. Food and Drug Administration (FDA), affirming its status as a next-generation manufacturing solution for CGTs.

• The platform’s design philosophy of delivering “superior biological performance alongside automation” enables developers to retain biological quality without sacrificing scalability or reproducibility, contrasting traditional manual or semi-automated CGT manufacturing methods.

• Ori has begun commercial roll-out of IRO: multiple instruments have been delivered to contract development and manufacturing organizations (CDMOs) and global pharmaceutical developers, demonstrating real-world adoption of the technology.

Conclusion from my interest in this company

Ori Biotech represents a critical evolution in the CGT field: by addressing the “translation gap” between groundbreaking cell/gene therapies and scalable, affordable manufacturing, the company helps make transformative therapies viable for widespread clinical use. The success of Ori’s platform would not only accelerate the pace of therapy development but also lower economic and logistical barriers which is an essential step toward delivering regenerative and personalized medicine to more patients worldwide.

One of Spiber’s flagship products is Brewed Protein™ fiber, a next-generation protein material made by fermenting plant-based sugars (such as sugarcane) with engineered microbes. The resulting bio-based, biodegradable fiber is used in collaboration products like The North Face’s “Moon Parka” and other outdoor apparel, aiming to replace petroleum-based synthetic fibers with more sustainable materials.

spiber.inc

Personally, I would like to work at Spiber, because it sits right at the intersection of synthetic biology, materials science, and sustainability. The idea of designing new protein materials with fermentation and then seeing them become real products—jackets, uniforms, even couture fashion—sounds intellectually exciting and also meaningful in terms of environmental impact.

Busness decaription:

Research , development, manufacture , sale, and import-export of agricultural chemicals and fertilisere. Manufacture amd sale of insecticides for non-agricultural use (insecticiees as general chemicals). Environmental management of building materials, including insect control, termite control, and moisture prevention.

One of their good product:

Dinotefuran: it is active ingredient of insecticide developed by this company. It is used for termite control for homes, flea and tick control for pets, and many other purposes.

I really have interest to join in this company to develop my skill to synthesize bioactive molecules

l  Scale

l  Syngenta Seeds & Crop Protection: Roughly 30,000+ employees across 90+ countries.

l  R&D Workforce: Over 5,000 scientists and researchers work specifically in Research & Development.

l  Location

l  Seeds Operational HQ: Downers Grove, Illinois, USA.

l  Key R&D Centers: Research Triangle Park (Raleigh, USA), Jealott’s Hill (UK), Uberlândia (Brazil), and Beijing (China).

l  Key product: Agrisure Viptera®(genetically modified insect-control maize variety)

l  Agrisure Viptera features Vip3A, a robust mode of action that offers unsurpassed control of a broad spectrum of lepidopteran corn pests. Both vegetative insecticidal proteins (VIP) and crystalline proteins (Cry) are derived from Bacillus thuringiensis (Bt). However, VIPs differ from Cry proteins by binding to different receptors within an insect’s mid-gut membrane.

l  It is widely considered the industry standard for controlling Lepidoptera pests, specifically the Fall Armyworm (Spodoptera frugiperda). This makes it a critical technology for farmers in the US, Brazil, and increasingly in Asia where Fall Armyworm has become a major threat.

Their business includes doing research, eevelopment, manufactures, sale, and import and export of agricultural chemicals and fertilizers. Manufactures and sale of insecticides for non agricultural use.

One of famous product from this company is dinotefuran. It is an active ingredient of insecticides developed bybthis company. It is used for termite control for homes, flea, and tick control for pest and many other purposes.

I really have interest to join in this company to develop my skill , to synthesize bio active molecules.